Get the Stockscreener App
36.48
0.68%
-0.25
Pre-market:
37.60
1.12
+3.07%
Crinetics Pharmaceuticals Inc stock is traded at $36.48, with a volume of 1.52M.
It is down -0.68% in the last 24 hours and down -33.22% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
See More
Previous Close:
$36.73
Open:
$36.63
24h Volume:
1.52M
Relative Volume:
1.96
Market Cap:
$3.38B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-9.7802
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-24.78%
1M Performance:
-33.22%
6M Performance:
-33.65%
1Y Performance:
-2.20%
1-Day Range:
$35.92
$37.29
1-Week Range:
$35.51
$47.56
52-Week Range:
$35.24
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
36.48 | 3.38B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.96 | 107.38B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.23 | 76.18B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
659.81 | 39.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.16 | 32.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.76 | 27.03B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Up 3.12%: This Is What Analysts Are Now Forecasting - Stocks Register
Crinetics falls after mid-stage trial data adrenal disorder therapy - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2%Here's Why - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by JPMorgan Chase & Co. - Defense World
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Grants Stock Options to 17 New Employees in Key Expansion Move - StockTitan
Crinetics reports positive results in CAH treatment study By Investing.com - Investing.com Australia
Crinetics stock falls after CAH therapy data (CRNX:NASDAQ) - Seeking Alpha
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2 - TipRanks
Crinetics reports positive results in CAH treatment study - Investing.com India
Crinetics Announces Positive Topline Results From Phase 2 - GlobeNewswire
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - Yahoo Finance
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Crinetics Pharmaceuticals’ SWOT analysis: stock poised for growth as pipeline advances - Investing.com Nigeria
Crinetics Pharmaceuticals' SWOT analysis: stock poised for growth as pipeline advances - Investing.com India
Crinetics stock maintains rating at Overweight on recent approval By Investing.com - Investing.com Canada
Trading (CRNX) With Integrated Risk Controls - Stock Traders Daily
Crinetics Pharmaceuticals chief sells shares worth $781,350 - Investing.com
Crinetics Pharmaceuticals chief sells shares worth $781,350 By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals (NASDAQ:CRNX) Trading Down 3.5%What's Next? - MarketBeat
Crinetics Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Raises Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness (NASDAQ:CRNX) - Seeking Alpha
Berkshire Hathaway Cl A (BRK-A-N) QuotePress Release - The Globe and Mail
Stifel Financial Corp Sells 520 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
JMP Securities Reaffirms Market Outperform Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - The Manila Times
Crinetics Pharma Strengthens Commercial Leadership, Names Veteran Launch Expert as Chief Commercial Officer - StockTitan
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Australia
Lord Abbett & CO. LLC Decreases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.89%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):